Please assess the completion status of the following clinical trial:

Trial Title: Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of T2DM in accordance to American Diabetes Association guidelines~* On metformin monotherapy or metformin in combination with a single allowable anti-hyperglycemic agent (AHA), DPP-4 inhibitors, meglitinides and AGIs are listed as allowable AHAs along with sulfonylureas prior to study participation.~* Body Mass Index (BMI) ≥18.0 kg/m\^2~* Male or female not of reproductive potential~* If a female of reproductive potential, agree to remain abstinent or to use (or have their partner use) 2 acceptable combinations of birth control while participating in the trial and for 14 days after the last use of study drug.~Exclusion Criteria:~* History or presence of type 1 diabetes mellitus or a history of ketoacidosis~* History of other specific types of diabetes (eg, genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant).~* A known hypersensitivity or intolerance to any sodium-glucose co-transporter 2 (SGLT2) inhibitor~* Use of the following prohibited therapeutic agents within 12 weeks of study participation: insulin, injectable anti-hyperglycemic agents, pioglitazone or rosiglitazone, another SGLT2 inhibitor, bromocriptine (Cycloset®), colesevelam (Welchol®), and any other non-approved anti-hyperglycemic therapy~* Known hypersensitivity or intolerance to metformin or glimepiride~* On a weight-loss program or medication or medication associated with weight changes and is not weight-stable (\>=5% change in body weight in the last 6 months)~* History of bariatric surgery less than 12 months prior to study participation~* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study participation~* Active, obstructive uropathy or an indwelling urinary catheter~* A history of malignancy ≤5 years prior to study participation, except for adequately treated basal or squamous cell skin cancer or in situ cervical cancer~* Known history of Human Immunodeficiency Virus (HIV)~* Blood dyscrasias or any disorders causing hemolysis or unstable red blood cells~* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or symptomatic gallbladder disease~* Any clinically significant malabsorption condition~* Being treated for hyperthyroidism, or on thyroid replacement therapy that has not been at a stable dose for at least 6 weeks prior to study participation~* Previous randomization in a study with ertugliflozin~* Participation in other studies involving investigational drug(s) within 30 days of study participation and/or during the pre-randomization period~* A surgical procedure within 6 weeks prior to study participation or planned major surgery during the trial~* A positive urine pregnancy test~* Pregnant or breast-feeding, or expecting to conceive during the trial, including 14 days following the last dose of study drug~* Undergoing hormonal therapy in preparation to donate eggs during the period of the trial, including 14 days following the last dose of study drug~* Consumption of more than 2 alcoholic drinks per day or engages in binge drinking~* Donation of blood or blood products within 6 weeks of study participation or plans to donate blood or blood products at any time during the trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg once daily (QD) from Day 1 to Week 104
- Ertugliflozin 15 mg (Type: EXPERIMENTAL): Ertugliflozin 15 mg QD from Day 1 to Week 104
- Glimepiride up to 8 mg (Type: ACTIVE_COMPARATOR): Glimepiride to a maximum of 8 mg QD from Day 1 to Week 104

Based on this trial design, predict the completion outcome and termination type (if applicable).